Janssen Pharmaceutica Nv

Dart Neuroscience, LLC

Pablo Garcia-Reynaga

Michael K Ameriks

Cynthia B Berry

Andrew V Samant

Jesus Alcazar

Brett C Bookser

Andrew Richard Hudson

Lino J Valdez

Benjamin Pratt

Joe Anh Tran

Marco Peters

Brian Ngo Laforteza

Aaron Thompson

Scott Burley

Jillian Basinger Thompson

J A Vega-Ramiro

Warren Stanfield Wade

Jimmy T Liang

Krisztián Biró

Lino Valdez

Thompson Jillian Basinger

Joe Tran

Substituted cyclohexyl chemical entities of Formula (I):

Substituted cyclohexyl compounds as NOP inhibitors

Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, Rand Rare defined herein.

Aminocyclobutanes as monoacylglycerol lipase modulators

Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, m, n, o, and p are defined herein.

Azaspirocycles as monoacylglycerol lipase modulators

Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R,, R, and L are as defined herein.

Cyclobutyl amide monoacylglycerol lipase modulators

Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, Rand Rare as defined herein.

Aryl piperidines as monoacylglycerol lipase modulators

3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R, R, and Rare defined herein.

Monoacylglycerol lipase modulators

Substituted cyclohexyl chemical entities of Formula (I): wherein R, G, and Rhave any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders. 

Substituted cyclohexyl compounds as NOP inhibiiors

Growing community of inventors

San Diego, CA, United States of America

Pablo Garcia-Reynaga